Nanomedicine (London, England) · 2026
Glutathione-responsive gambogic acid-conjugated carboxymethyl chitosan/graphene quantum dot nanoparticles for chemo-photothermal-photodynamic synergistic therapy of drug-resistant breast cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Shuzhen, Shao Su
Аннотация
AIMS: Breast cancer (BC) remains the most prevalent malignancy in women, with conventional chemotherapy limited by drug resistance. This study develops a glutathione (GSH)-responsive nanoplatform combining chemotherapy with phototherapy against drug-resistant BC.
METHODS: Gambogic acid (GA) was conjugated to carboxymethyl chitosan via disulfide bonds (GA-SS-CMCS, GSC), then loaded with graphene quantum dots (GQDs) to form GSC@GQD nanocomposites. The formulation was characterized by TEM, DLS, and NMR; photothermal performance, drug release, ROS generation, hemocompatibility, and anti-tumor efficacy were evaluated in MCF-7, MCF-7/ADR cells and MCF-7/ADR xenografts.
RESULTS: GSC@GQD showed uniform morphology (~180 nm), GSH-triggered GA release (94% at 48 h), and hemolysis <5%. Under 808 nm irradiation, GSC@GQD raised temperature by 20 °C (vs. 9 °C for free GQDs), induced intracellular ROS accumulation, and achieved apoptosis rates of 86% (MCF-7) and 76% (MCF-7/ADR). In vivo, GSC@GQD + NIR suppressed tumor growth with satisfactory biosafety.
CONCLUSIONS: GSC@GQD integrates chemotherapy, photodynamic and photothermal therapy into a GSH-responsive platform, offering a promising strategy against drug-resistant BC.
METHODS: Gambogic acid (GA) was conjugated to carboxymethyl chitosan via disulfide bonds (GA-SS-CMCS, GSC), then loaded with graphene quantum dots (GQDs) to form GSC@GQD nanocomposites. The formulation was characterized by TEM, DLS, and NMR; photothermal performance, drug release, ROS generation, hemocompatibility, and anti-tumor efficacy were evaluated in MCF-7, MCF-7/ADR cells and MCF-7/ADR xenografts.
RESULTS: GSC@GQD showed uniform morphology (~180 nm), GSH-triggered GA release (94% at 48 h), and hemolysis <5%. Under 808 nm irradiation, GSC@GQD raised temperature by 20 °C (vs. 9 °C for free GQDs), induced intracellular ROS accumulation, and achieved apoptosis rates of 86% (MCF-7) and 76% (MCF-7/ADR). In vivo, GSC@GQD + NIR suppressed tumor growth with satisfactory biosafety.
CONCLUSIONS: GSC@GQD integrates chemotherapy, photodynamic and photothermal therapy into a GSH-responsive platform, offering a promising strategy against drug-resistant BC.